Cdk5 Protein Inhibition and Aβ42 Increase BACE1 Protein Level in Primary Neurons by a Post-transcriptional Mechanism
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Close proximity to plaques is associated with presynaptic dystrophy and Aβ42 oligomers increase BACE1 levels in cultured neurons [48,49], thus implicating Aβ neurotoxicity in these processes.”
In the citing paper
“we previously observed that 5 days of treatment with 1 and 2 μM Aβ42 oligomers did not increase caspase 3 cleavages in primary neurons [49].”
In the citing paper
“we previously showed that 5 days of treatment with 1 or 2 μM Aβ42 oligomers caused no significant increase of activated caspase 3 in primary neurons [49].”
In the citing paper
“Neurite beading, microtubule accumulation in varicosities (arrowheads), and microtubule fragmentation (arrows) in neurites were present 3.5 h after Aβ42 addition, in the absence of significant cell death or BACE1 elevation[49].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769
RetractedOakley, H., Cole, S. L., Logan, S., Maus, E., Shao, P., Craft, J., Guillozet-Bongaarts, A., Ohno, M., Disterhoft, J., Van Eldik, L., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.1202-06.2006 · Cited by 3,530 · cited 2×
“The 5XFAD transgenic mouse model carries fivemutations associatedwith familial Alzheimer disease and begins generating high levels of A 42 at 6 weeks of age, soon after the onset of transgene expression (37).”
BackgroundMethodSelf-citationCitron, M., Oltersdorf, T., Haass, C., McConlogue, L., Hung, A. Y., Seubert, P., Vigo-Pelfrey, C., Lieberburg, I., & Selkoe, D. J. (1992) · Nature · doi:10.1038/360672a0 · Cited by 1,757
Shankar, G. M., Bloodgood, B. L., Townsend, M., Walsh, D. M., Selkoe, D. J., & Sabatini, B. L. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.4970-06.2007 · Cited by 1,592 · cited 1×
“This synaptic loss may be responsible for memory impairment inAD (48, 52) before frank neuronal loss, so understanding detrimental changes in synapses and neurites exposed to high levels of oligomeric and/or fibrillar A 42 near plaques may suggest novel therapeutic approaches to slowmemory loss.”
BackgroundRegulation of NMDA receptor trafficking by amyloid-β
Snyder, E. M., Nong, Y., Almeida, C. G., Paul, S., Moran, T., Choi, E. Y., Nairn, A. C., Salter, M. W., Lombroso, P. J., Gouras, G. K., et al. (2005) · Nature Neuroscience · doi:10.1038/nn1503 · Cited by 1,561
Mullan, M., Crawford, F., Axelman, K., Houlden, H., Lilius, L., Winblad, B., & Lannfelt, L. (1992) · Nature Genetics · doi:10.1038/ng0892-345 · Cited by 1,513 · cited 1×
“Familial AD (FAD) cases caused by the APP Swedish mutation (K670N,M671L) (12) that enhances cleavage by BACE1 (13) suggest that increased activity of BACE1 may be sufficient to induce Alzheimer disease in humans.”
BackgroundLacor, P. N., Buniel, M. C., Furlow, P. W., Sanz Clemente, A., Velasco, P. T., Wood, M., Viola, K. L., & Klein, W. L. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.3501-06.2007 · Cited by 1,188 · cited 1×
“This synaptic loss may be responsible for memory impairment inAD (48, 52) before frank neuronal loss, so understanding detrimental changes in synapses and neurites exposed to high levels of oligomeric and/or fibrillar A 42 near plaques may suggest novel therapeutic approaches to slowmemory loss.”
BackgroundIn vitro characterization of conditions for amyloid-β peptide oligomerization and fibrillogenesis
Stine, W. B., Dahlgren, K. N., Krafft, G. A., & LaDu, M. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210207200 · Cited by 1,015 · cited 1×
“A 42 Preparation—A 42 oligomers and fibrils were prepared as described previously (38).”
MethodLuo, Y., Bolon, B., Kahn, S., Bennett, B. D., Babu-Khan, S., Denis, P., Fan, W., Kha, H., Zhang, J., Gong, Y., et al. (2001) · Nature Neuroscience · doi:10.1038/85059 · Cited by 1,001
Self-citationSynaptic Targeting by Alzheimer's-Related Amyloid β Oligomers
Lacor, P. N., Buniel, M. C., Chang, L., Fernandez, S. J., Gong, Y., Viola, K. L., Lambert, M. P., Velasco, P. T., Bigio, E. H., Finch, C. E., et al. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.3432-04.2004 · Cited by 954
Research works printed but not linked: 39
- Vassar, 1999, β-Secretase cleavage of Alzheimer amyloid precursor protein by the transmembrane aspartic protease BACE, Science, 286, 735, 10.1126/science.286.5440.735 · DOI · Paper page
- Cai, 2001, BACE1 is the major β-secretase for generation of Aβ peptides by neurons, Nat. Neurosci., 4, 233, 10.1038/85064 · DOI · Paper page
- Kao, 2004, BACE1 suppression by RNA interference in primary cortical neurons, J. Biol. Chem., 279, 1942, 10.1074/jbc.M309219200 · DOI · Paper page
- Singer, 2005, Targeting BACE1 with siRNAs ameliorates Alzheimer disease neuropathology in a transgenic model, Nat. Neurosci., 8, 1343, 10.1038/nn1531 · DOI · Paper page
- Bodendorf, 2002, Expression of human β-secretase in the mouse brain increases the steady-state level of β-amyloid, J. Neurochem., 80, 799, 10.1046/j.0022-3042.2002.00770.x · DOI · Paper page
- Chiocco, 2004, Altered amyloid-β metabolism and deposition in genomic-based β-secretase transgenic mice, J. Biol. Chem., 279, 52535, 10.1074/jbc.M409680200 · DOI · Paper page
- Mohajeri, 2004, Transgenic BACE expression in mouse neurons accelerates amyloid plaque pathology, J. Neural Transm., 111, 413, 10.1007/s00702-003-0057-z · DOI
- Fukumoto, 2002, β-Secretase protein and activity are increased in the neocortex in Alzheimer disease, Arch. Neurol., 59, 1381, 10.1001/archneur.59.9.1381 · DOI · Paper page
- Li, 2004, Amyloid β peptide load is correlated with increased β-secretase activity in sporadic Alzheimer disease patients, Proc. Natl. Acad. Sci. U.S.A., 101, 3632, 10.1073/pnas.0205689101 · DOI · Paper page
- O'Connor, 2008, Phosphorylation of the translation initiation factor eIF2α increases BACE1 levels and promotes amyloidogenesis, Neuron, 60, 988, 10.1016/j.neuron.2008.10.047 · DOI · Paper page
- Dominguez, 2005, Phenotypic and biochemical analyses of BACE1- and BACE2-deficient mice, J. Biol. Chem., 280, 30797, 10.1074/jbc.M505249200 · DOI · Paper page
- Ohno, 2006, Temporal memory deficits in Alzheimer mouse models. Rescue by genetic deletion of BACE1, Eur. J. Neurosci., 23, 251, 10.1111/j.1460-9568.2005.04551.x · DOI · Paper page
- Ohno, 2004, BACE1 deficiency rescues memory deficits and cholinergic dysfunction in a mouse model of Alzheimer disease, Neuron, 41, 27, 10.1016/S0896-6273(03)00810-9 · DOI · Paper page
- Zhang, 2009, β-Secretase-1 elevation in transgenic mouse models of Alzheimer disease is associated with synaptic/axonal pathology and amyloidogenesis. Implications for neuritic plaque development, Eur. J. Neurosci., 30, 2271, 10.1111/j.1460-9568.2009.07017.x · DOI · Paper page
- Lee, 2000, Neurotoxicity induces cleavage of p35 to p25 by calpain, Nature, 405, 360, 10.1038/35012636 · DOI · Paper page
- Patrick, 1999, Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration, Nature, 402, 615, 10.1038/45159 · DOI · Paper page
- Cruz, 2006, p25/cyclin-dependent kinase 5 induces production and intraneuronal accumulation of amyloid β in vivo, J. Neurosci., 26, 10536, 10.1523/JNEUROSCI.3133-06.2006 · DOI · Paper page
- Wen, 2008, Transcriptional regulation of β-secretase by p25/cdk5 leads to enhanced amyloidogenic processing, Neuron, 57, 680, 10.1016/j.neuron.2008.02.024 · DOI · Paper page
- Louneva, 2008, Caspase-3 is enriched in postsynaptic densities and increased in Alzheimer disease, Am. J. Pathol., 173, 1488, 10.2353/ajpath.2008.080434 · DOI · Paper page
- Selznick, 1999, In situ immunodetection of neuronal caspase-3 activation in Alzheimer disease, J. Neuropathol. Exp. Neurol., 58, 1020, 10.1097/00005072-199909000-00012 · DOI · Paper page
- Stadelmann, 1999, Activation of caspase-3 in single neurons and autophagic granules of granulovacuolar degeneration in Alzheimer disease. Evidence for apoptotic cell death, Am. J. Pathol., 155, 1459, 10.1016/S0002-9440(10)65460-0 · DOI · Paper page
- Su, 2001, Activated caspase-3 expression in Alzheimer and aged control brain. Correlation with Alzheimer pathology, Brain Res., 898, 350, 10.1016/S0006-8993(01)02018-2 · DOI · Paper page
- Borghi, 2002, Increase of cdk5 is related to neurofibrillary pathology in progressive supranuclear palsy, Neurology, 58, 589, 10.1212/WNL.58.4.589 · DOI · Paper page
- Nguyen, 2002, Controversies over p25 in Alzheimer disease, J. Alzheimer's Dis., 4, 123, 10.3233/JAD-2002-4207 · DOI
- Takashima, 2001, Involvement of cyclin-dependent kinase5 activator p25 on Tau phosphorylation in mouse brain, Neurosci. Lett., 306, 37, 10.1016/S0304-3940(01)01864-X · DOI
- Tandon, 2003, Brain levels of CDK5 activator p25 are not increased in Alzheimer or other neurodegenerative diseases with neurofibrillary tangles, J. Neurochem., 86, 572, 10.1046/j.1471-4159.2003.01865.x · DOI · Paper page
- Taniguchi, 2001, Calpain-mediated degradation of p35 to p25 in postmortem human and rat brains, FEBS Lett., 489, 46, 10.1016/S0014-5793(00)02431-5 · DOI · Paper page
- Yoo, 2001, p25 protein in neurodegeneration, Nature, 411, 763, 10.1038/35081146 · DOI
- Bennett, 2005, The Rush Memory and Aging Project. Study design and base-line characteristics of the study cohort, Neuroepidemiology, 25, 163, 10.1159/000087446 · DOI · Paper page
- Lesné, 2008, Plaque-bearing mice with reduced levels of oligomeric amyloid-β assemblies have intact memory function, Neuroscience, 151, 745, 10.1016/j.neuroscience.2007.10.054 · DOI
- Shankar, 2008, Amyloid-β protein dimers isolated directly from Alzheimer brains impair synaptic plasticity and memory, Nat. Med., 14, 837, 10.1038/nm1782 · DOI · Paper page
- Lee, 2003, APP processing is regulated by cytoplasmic phosphorylation, J. Cell Biol., 163, 83, 10.1083/jcb.200301115 · DOI · Paper page
- Zheng, 2002, A peptide derived from cyclin-dependent kinase activator (p35) specifically inhibits Cdk5 activity and phosphorylation of Tau protein in transfected cells, Eur. J. Biochem., 269, 4427, 10.1046/j.1432-1033.2002.03133.x · DOI · Paper page
- Kerokoski, 2001, The levels of cdk5 and p35 proteins and Tau phosphorylation are reduced during neuronal apoptosis, Biochem. Biophys. Res. Commun., 280, 998, 10.1006/bbrc.2001.4240 · DOI
- Zempel, 2010, Aβ oligomers cause localized Ca(2+) elevation, missorting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines, J. Neurosci., 30, 11938, 10.1523/JNEUROSCI.2357-10.2010 · DOI · Paper page
- Yamin, 2009, NMDA receptor-dependent signaling pathways that underlie amyloid β-protein disruption of LTP in the hippocampus, J. Neurosci. Res., 87, 1729, 10.1002/jnr.21998 · DOI · Paper page
- Mengesdorf, 2002, Down-regulation of Parkin protein in transient focal cerebral ischemia. A link between stroke and degenerative disease?, Proc. Natl. Acad. Sci. U.S.A., 99, 15042, 10.1073/pnas.232588799 · DOI
- Sheng, 2003, The β-amyloid-related proteins presenilin 1 and BACE1 are axonally transported to nerve terminals in the brain, Exp. Neurol., 184, 1053, 10.1016/j.expneurol.2003.08.018 · DOI · Paper page
- Jacobs, 2006, Cyclin-dependent kinase 5, Munc18a, and Munc18-interacting protein 1/X11α protein up-regulation in Alzheimer disease, Neuroscience, 138, 511, 10.1016/j.neuroscience.2005.11.017 · DOI
Cited by
BACE1 inhibitor drugs in clinical trials for Alzheimer’s disease
Vassar, R. (2014) · Alzheimer's Research & Therapy · doi:10.1186/s13195-014-0089-7 · Cited by 410
Self-citationAutophagy and Alzheimer’s Disease: From Molecular Mechanisms to Therapeutic Implications
Uddin, M. S., Stachowiak, A., Mamun, A. A., Tzvetkov, N. T., Takeda, S., Atanasov, A. G., Bergantin, L. B., Abdel-Daim, M. M., & Stankiewicz, A. M. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00004 · Cited by 395
Sadleir, K. R., Kandalepas, P. C., Buggia-Prévot, V., Nicholson, D. A., Thinakaran, G., & Vassar, R. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1558-9 · Cited by 294
Self-citationChami, L., & Checler, F. (2012) · Molecular Neurodegeneration · doi:10.1186/1750-1326-7-52 · Cited by 168
Bisecting GlcNAc modification stabilizes BACE1 protein under oxidative stress conditions
Kizuka, Y., Nakano, M., Kitazume, S., Saito, T., Saido, T. C., & Taniguchi, N. (2016) · Biochemical Journal · doi:10.1042/bj20150607 · Cited by 85
Metadata
- Authors
- Sadleir, K. R., & Vassar, R.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2012-03
- Volume
- 287
- Issue
- 10
- Pages
- 7224-7235
- ISSN
- 0021-9258
- Cited by
- 52
- References
- 25
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 3123 d)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cdk5 Protein Inhibition and Aβ42 Increase BACE1 Protein Level in Primary Neurons by a Post-transcriptional Mechanism. https://app.cochat.ai/papers/10.1074/jbc.m111.333914
- The paper
- Sadleir, K. R., & Vassar, R. (2012). Cdk5 Protein Inhibition and Aβ42 Increase BACE1 Protein Level in Primary Neurons by a Post-transcriptional Mechanism. Journal of Biological Chemistry. https://doi.org/10.1074/jbc.m111.333914
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.